Comparative Pharmacology
Head-to-head clinical analysis: AMINOPHYLLIN versus AMINOPHYLLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOPHYLLIN versus AMINOPHYLLINE.
AMINOPHYLLIN vs AMINOPHYLLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective phosphodiesterase inhibitor, increasing intracellular cAMP and cGMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.
Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.
Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.
None Documented
None Documented
Clinical Note
moderateAminophylline + Gatifloxacin
"The metabolism of Gatifloxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Rosoxacin
"The metabolism of Rosoxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Levofloxacin
"The metabolism of Levofloxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Trovafloxacin
Terminal elimination half-life: 3–12 hours in adults (mean ~6 hours); prolonged in hepatic impairment, heart failure, or COPD (up to 30 hours); shorter in smokers (4–5 hours due to CYP1A2 induction); neonates: 20–40 hours.
Adults: 7-9 hours (nonsmokers), 4-5 hours (smokers), 10-20 hours (neonates, hepatic impairment, CHF).
Renal excretion of unchanged drug accounts for ~10%, with the remainder eliminated as metabolites (caffeine, 3-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid) via urine; minimal biliary/fecal elimination (<5%).
Renal: ~10% unchanged; hepatic metabolism (N-demethylation, oxidation) accounts for >80% of elimination; <1% fecal.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator
"The metabolism of Trovafloxacin can be decreased when combined with Aminophylline."